^
2ms
Advancements in TGF-β Targeting Therapies for Head and Neck Squamous Cell Carcinoma. (PubMed, Cancers (Basel))
While preclinical data have demonstrated the great anti-tumorigenic potential of TGF-β inhibitors, the underwhelming results of ongoing and completed clinical trials highlight the difficulty actualizing these benefits into clinical practice. This topical review will discuss the relevant preclinical and clinical findings for TGF-β inhibitors in HNSCC and will explore the potential role of patient stratification in the development of this therapeutic strategy.
Review • Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
bintrafusp alfa (M7824) • retlirafusp alfa (SHR-1701) • ficerafusp alfa (BCA101) • LY3200882 • dalantercept (ACE-041)
over2years
Targeting the transforming growth factor-beta signaling pathway in the treatment of gynecologic cancer. (PubMed, Curr Cancer Drug Targets)
There are several TGF-β inhibitors which are potential anticancer agents and are undergoing clinical trials in cancer, including galunisertib, dalantercept, and vigil. There is a growing body of data showing the potential therapeutic impact of targeting the TGF-β pathway in different cancer types, although further studies are still warranted to explore the value of this strategy and finding the most appropriate patients who could most benefit from therapy.
Journal
|
TGFB1 (Transforming Growth Factor Beta 1)
|
galunisertib (LY2157299) • dalantercept (ACE-041)